Crispr Therapeut - CRSP STOCK NEWS

CRISPR Therapeutics (Nasdaq: CRSP) celebrates the recognition of co-founder Professor Emmanuelle Charpentier, awarded the 2020 Nobel Prize in Chemistry for her contributions to the CRISPR/Cas9 technology. This honor reflects the significant impact of CRISPR research on gene-based therapies for serious diseases. CRISPR Therapeutics, leveraging this technology, aims to develop transformative medicines across various disease areas, notably in oncology and rare diseases. The company remains committed to advancing gene editing innovations amid the growing importance of genetic research.

CRISPR Therapeutics (Nasdaq: CRSP) announced its senior management will participate in two upcoming investor conferences in August 2020. The William Blair Biotech Focus Conference is scheduled for August 6 at 1:00 p.m. ET, while the Canaccord Genuity 40th Annual Growth Conference will take place on August 13 at 2:30 p.m. ET. Live webcasts of these events will be available on the company's website, with archives accessible for 14 days post-presentation. CRISPR Therapeutics focuses on developing gene-based medicines utilizing its innovative CRISPR/Cas9 platform.

CRISPR Therapeutics (Nasdaq: CRSP) reported its Q2 2020 results, highlighting a net loss of $79.7 million, up from $53.7 million in Q2 2019. The company re-initiated dosing in clinical trials for CTX001, which targets severe hemoglobinopathies and has received both Orphan Drug and RMAT designations from the FDA. Cash and cash equivalents rose to $945.1 million, aided by a $517.5 million public offering. However, total collaboration revenue was less than $0.1 million, down from $0.3 million a year ago, indicating a revenue decline amid increased R&D and G&A expenses.

CRISPR Therapeutics (Nasdaq:CRSP) announced a public offering of 6,428,572 common shares at $70.00 each, aiming for gross proceeds of approximately $450 million. Underwriters have a 30-day option to buy an additional 964,285 shares. The offering will close around July 6, 2020, pending customary conditions. This follows a previously filed shelf registration statement with the SEC. Major underwriters include Goldman Sachs, BofA Securities, and Jefferies. The company is focused on gene-based medicines for serious diseases using its CRISPR/Cas9 platform.

CRISPR Therapeutics has announced a public offering of $325 million in common shares, with an over-allotment option of $48.75 million. The offering is managed by Goldman Sachs, BofA Securities, and Jefferies, and is subject to market conditions. The shares will be sold under an SEC registration statement filed in 2018. The company focuses on transformative gene-based medicines using the CRISPR/Cas9 platform, based in Zug, Switzerland, and Cambridge, Massachusetts.

CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals presented promising results for CTX001, a gene-editing therapy targeting transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD) at the EHA virtual congress. Notable outcomes include two beta thalassemia patients achieving transfusion independence at 5 and 15 months post-infusion, and one SCD patient remaining free from vaso-occlusive crises at 9 months. All treated patients have successfully engrafted and demonstrated significant improvements in hemoglobin levels and other health metrics, showcasing the potential of CTX001 as a transformative therapeutic option.

CRISPR Therapeutics has announced its participation in two virtual investor conferences in June 2020. The Jefferies Global Healthcare Conference will take place on June 2, 2020, at 1:30 p.m. ET. The company will also join the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020, at 9:40 a.m. ET. Investors can access live webcasts of both events on the company's website, with a replay available for 14 days post-presentation. CRISPR Therapeutics focuses on developing gene-based medicines for serious diseases utilizing its proprietary CRISPR/Cas9 technology.

CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals (Nasdaq: VRTX) announced that new data from ongoing Phase 1/2 trials of CTX001, a gene-editing therapy, will be presented at the EHA Congress from June 11-14, 2020. The presentations will include 12 months of follow-up data from the CLIMB-111 trial for transfusion-dependent beta thalassemia and 6 months of data from the CLIMB-121 trial for severe sickle cell disease. CTX001 aims to elevate fetal hemoglobin levels, potentially alleviating treatment burdens for patients. The collaboration focuses on innovative treatments for serious diseases.

CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals (VRTX) announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX001, a gene-edited therapy for sickle cell disease and beta thalassemia. This designation marks a crucial regulatory achievement and indicates CTX001's potential to address serious health conditions. RMAT designation allows for expedited development processes, enhancing the pathway to potential approval. CRISPR is set to present additional clinical data for CTX001 later this year, bolstering the collaboration's prospects in addressing unmet medical needs.